Clinical Trial

Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Recruiting
View on ClinicalTrials.gov →
Summary
The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-17.
Trial Details
NCT Number NCT06516406
Lead Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis
Enrollment 1,055 participants
Start Date 2022-05-06
Primary Completion 2032-05-31 (estimated)
Study Completion 2032-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-05